atepeq/tico19 huggingface dataset:
It further recommends using an alcohol-based hand sanitiser with at least 60% alcohol, but only when soap and water are not readily available.For areas where commercial hand sanitisers are not readily available, the WHO provides two formulations for local production.
O ɗon feela bo'o huwugo be kuje laɓɓinugo juɗe je mari alkol pettum man 60%, amma sey sna to sabulu be ndiyam wala. Ha wakkereji je wala sippol kuje laɓɓinugo juɗe, WHO ɗon hokka mon daɓare waɗugo ɗum be hoore moɗon.
In these formulations, the antimicrobial activity arises from ethanol or isopropanol.
Ha nder laahalji ndu, kugal mbardol gilɗiji ndu wangi gal ethanol mala isopropanol.
Hydrogen peroxide is used to help eliminate bacterial spores in the alcohol; it is "not an active substance for hand antisepsis".
Hydrogen peroxide naffan ngam nattinugo bakteriyaji ha nder alkol; latay "kuje je wondi ngam laɓɓinugo juɗe".
Glycerol is added as a humectant.
Glycerol ɗon ɓesdi bana kuje sofnol.
People are managed with supportive care, which may include fluid therapy, oxygen support, and supporting other affected vital organs.
Yimɓe hokkama suklare ngam fadol, je footi larna hurgol be njaaram, wallende be heendu, be wallugo kujeji ɓaandu feere je ɗon kanduɗum.
The CDC recommends that those who suspect they carry the virus wear a simple face mask.
CDC ɗon feela yo'o ɓe'en je tammi roondugo viriis ɓoorna mask suudugo yeeso.
Extracorporeal membrane oxygenation (ECMO) has been used to address the issue of respiratory failure, but its benefits are still under consideration.
Extracorporeal membrane oxygenation (ECMO) naffiki no ngam hurgugo sababu pofɗe, amma ribaji maɗa ɗon do lartol ha jonta.
Personal hygiene and a healthy lifestyle and diet have been recommended to improve immunity.
Laɓɓinol ɓaandu be jonde e nyamɗe boɗɗe feelama ngam ɓesdugo fadol.
Supportive treatments may be useful in those with mild symptoms at the early stage of infection.The WHO and Chinese National Health Commission have published recommendations for taking care of people who are hospitalised with COVID-19.
Hurgolji walllende footi naffa be maandolji je nyaɗay ha fuɗɗam nyau. WHO be Chinese National Health Commission wangini feeloji ngam suklugo do yimɓe je ɗon woni ha nder suudu lekki je mari COVID-19.
Intensivists and pulmonologists in the U.S. have compiled treatment recommendations from various agencies into a free resource, the IBCC.
Huwooɓe be jaawal mala ɗon sukla do fuffu ha Lesɗe America wurtini feeloji ha geeɓeji jur ngam wallende meere, IBCC.
As of April 2020, there is no specific treatment for COVID-19.
Ha Aviiril 2020, woda hurgol COVID-19 je kkanduɗum.
For symptoms, some medical professionals recommend paracetamol (acetaminophen) over ibuprofen for first-line use.
Ko larni matinolji, huwooɓe do jam ɓaandu feeli paracetamol (acetaminophen) do ibuprofen ha nyauɓe.
Precautions must be taken to minimise the risk of virus transmission, especially in healthcare settings when performing procedures that can generate aerosols, such as intubation or hand ventilation.
Sey huwa be hakkika ngam ustugo sababu raɓɓugo gilɗi, ɓurna fu ha nder wakkerji jam ɓaanɗu ha yakke waɗugo laahalji je footi footi wurtina pofɗe, bana nastinol kuje ha nder daande mala fartol hendu be jungo.
For healthcare professionals caring for people with COVID-19, the CDC recommends placing the person in an Airborne Infection Isolation Room (AIIR) in addition to using standard precautions, contact precautions and airborne precautions.The CDC outlines the guidelines for the use of personal protective equipment (PPE) during the pandemic.
Ha huwoɓe je sulata do jam ɓaandu yimɓ be COVID-19, CDC ɗon feela wattugo goɗɗo man ha nder Airborne Infection Isolation Room (AIIR) HA ɓesdugo do kugal be hakkika. CDC ɗon wangini dabareji ngam fadol hoore mum (PPE) ha wakati nyau duniyaru ndu.
The recommended gear is: PPE gown, respirator or facemask, eye protection, and medical gloves.When available, respirators (instead of facemasks) are preferred.
Kujeji je ɗon feeli ngam ɓornugo: ngapaleewol PPE, ordo fuffugo mala mask suddugo yeeso, kuje fadugo gite, be kujeji suddugo juɗe. To wodi, ordo pofɗe (do mask sudugo yeeso) ɓuri naffugo.
N95 respirators are approved for industrial settings but the FDA has authorised the masks for use under an Emergency Use Authorisation (EUA).
Ordoji fuffugo N95 jarfama ngam huwugo ha wakkereji tagle kujeji amma FDA jarfi maskji ndu nder kugal Emergency Use Authorisation (EUA).
They are designed to protect from airborne particles like dust but effectiveness against a specific biological agent is not guaranteed for off-label uses.
Kugal maɓɓe lati fadugo ngam kujeji je hendu roondi bana coolaaje amma naffuda man ngam gilɗi je ɗon aandin footay hokka jabbuye je fakatre.
When masks are not available, the CDC recommends using face shields or, as a last resort, homemade masks.
To maskji wala, CDC ɗon feela ɓornugo kuje fadugo yeeso mala, bana dabare je ragare, maskji je waɗama ha saare.
Most cases of COVID-19 are not severe enough to require mechanical ventilation or alternatives, but a percentage of cases are.
Nyauɓe COVID-19 ɓurna fu ɗon emma fartol hendu be ordo mala dabare feere, NS
The type of respiratory support for individuals with COVID-19 related respiratory failure is being actively studied for people in hospital, with some evidence that intubation can be avoided with a high flow nasal cannula or bi-level positive airway pressure.
Irin wallende pofɗe ha yimɓe je mari nyau COVID-19 be saɗirma nder pofɗe ɗon do ekkitol ngam yimɓe je ɗon woni ha suudu lekki, be sappinol je footi acca nastirde kuje fuffugo ha nder daande be illam kine je nyaɗum be saɗirmaji pofɗe.
Whether either of these two leads to the same benefit for people who are critically ill is not known.
To ɗiɗi fu ɗon yara ha ribaji fu je naffata yimɓe je ɗon mari nyau man maasin wala fammugo tawon.
Some doctors prefer staying with invasive mechanical ventilation when available because this technique limits the spread of aerosol particles compared to a high flow nasal cannula.Severe cases are most common in older adults (those older than 60 years, and especially those older than 80 years).
Lekkitoɓe feere yardi wondugo be fartol hendu be ordo to wodi ngam dabare ndu ɗon usta sankittol kujeji je heendu footi horta to foondi be illam kine je nyaɗum. Nyau ndu ɓuri nyaɗugo ha ndotti'en (ɓe'en je ɓuri duɓɓi 60, ɓurna fu ɓe'en je ɓuri duɓɓi 80).
Many developed countries do not have enough hospital beds per capita, which limits a health system's capacity to handle a sudden spike in the number of COVID-19 cases severe enough to require hospitalisation.
Lesɗe je ɗon mari aandal e risku ɗuɗɗum maray leesoji suudi lekki je yimbe fu, kanjuum wadi footay yimɓe fu heɓɓa nyambitol to limgal nyauɓe COVID-19 je mari haaje wondugo ha suudu lekki wa'i.
One study in China found 5% were admitted to intensive care units, 2.3% needed mechanical support of ventilation, and 1.4% died.
Ekkitol feere ha Cayna sappini yo'o 5% neldotto ha geeɓe suklare nyaɗum, 2.3% mari no haaje fartol heendu gal ordo, be 1.4% maynama.
In China, approximately 30% of people in hospital with COVID-19 are eventually admitted to ICU.
Ha Cayna, ɓadi 30% yimɓe ha suudu lekki be COVID-19 neldotto ha ICU.
Mechanical ventilation becomes more complex as acute respiratory distress syndrome (ARDS) develops in COVID-19 and oxygenation becomes increasingly difficult.
Fartol gal ordo latan caɗɗungel masitin to saɗirma nder pofɗe ɗon fuɗɗa (ARDS) ha COVID-19 be hendu je ɗon lata caɗɗum masitin.
Ventilators capable of pressure control modes and high PEEP are needed to maximise oxygen delivery while minimising the risk of ventilator-associated lung injury and pneumothorax.
Ordoji waɗugo heendu je footi ayna harloji be PEEP je mauni naffan ngam ɓesdugo heendu ha yakke ustugo sababu huudure do fuffu be pneunomothorax ngam ordo fartugo hendu.
High PEEP may not be available on older ventilators.
PEEP footi tawakke ha nder ordoji pofɗe je aran.
Research into potential treatments started in January 2020, and several antiviral drugs are in clinical trials.
Teffol ngam tammunde hurgolji fuɗɗi ha Zaanviye 2020 be lekki mbardugo viriisji jur ɗon do foondolji ha suudu lekki.
Remdesivir appears to be the most promising.
Remdesivir lati bana ɓuri naffugo.
Although new medications may take until 2021 to develop, several of the medications being tested are already approved for other uses or are already in advanced testing.
Ko to lekki keese footi yotta ha 2021 hiddeko wurtugo, lekki jur ɗon do lartol e lati jaɓɓama ngam kugal feere mala ɗon do lartol je dayɗum timmi.
Antiviral medication may be tried in people with severe disease.
Lekki mbardugo viriis footi foondotto ha yimɓe be nyau nyaɗum.
The WHO recommended volunteers take part in trials of the effectiveness and safety of potential treatments.The FDA has granted temporary authorisation to convalescent plasma as an experimental treatment in cases where the person's life is seriously or immediately threatened.
WHO feeli foondooɓe wonda ha nder lartol naffuda be jam hurgolji je footi yotta. FDA hokki jarfuye be wakati ha neebam iyam bana hurgol foondol ha nyauɓe je nyau maɓɓe ɓuri nyaɗugo.
It has not undergone the clinical studies needed to show it is safe and effective for the disease.
Sallinay ekkitolji suudu lekki je aandin no ngam sappinugo lati kanduɗum e wodi naffitirki ngam nyau.
In February 2020, China launched a mobile app to deal with the disease outbreak.
Ha Feviriye 2020, Cayna wurtini applikasion feere je aynata sankittol nyau ndu.
Users are asked to enter their name and ID number.
Howooɓe be majuum emmotto ngam nastinugo lamba mandirɗum maɓɓe.
The app is able to detect 'close contact' using surveillance data and therefore a potential risk of infection.
Applikasion ndu footi maanda "ngidol je ɓaditi" gal huwidugo be matinolji aynol e nden kadi bana sababu raɓɓugo nyau.
Every user can also check the status of three other users.
Kala huwoowo be majuum footi larta wonde yimɓe feere tati je ɗon mari.
If a potential risk is detected, the app not only recommends self-quarantine, it also alerts local health officials.Big data analytics on cellphone data, facial recognition technology, mobile phone tracking and artificial intelligence are used to track infected people and people whom they contacted in South Korea, Taiwan and Singapore.
To wodi sababu feere ɗon tawi, applikasion ndu feelatta mon wondugo seera tan, amma matinan bo'o huwooɓe do jam ɓaandu wakkere ndu. Matinolji lartol ɗuɗɗum do matinolji telefon, dabare maandirɗum yeeso, tokkitol wakkere woonde be aandal ordo naffan ngam tawittugo yimɓe je ɗon mari nyau be yimɓe be yimɓe je ɓe ngidi be maɓɓe ha South Koorea, Taiwan be Singapore.
In March 2020, the Israeli government enabled security agencies to track mobile phone data of people supposed to have coronavirus.
Ha Maars 2020, ngomna Israyila hokki jarfuye ha geeɓeji jam ngam tokkitugo mandolji telefon yimɓe bana mari nyau koronaviriis.
The measure was taken to enforce quarantine and protect those who may come into contact with infected citizens.
Dabare ndu hoosama ngam aynugo do wondugo ha seera be fadugo ɓe'en je footi ngida be yimɓe je ɗon mari nyau.
Also in March 2020, Deutsche Telekom shared aggregated phone location data with the German federal government agency, Robert Koch Institute, in order to research and prevent the spread of the virus.
Fahin ha Maars 2020, Deutsche Telekon sendi matinolji mandol wakkereji telefon je ɗon hawti be geeɓe ngomna lesdi Jaamani, Robert Koch Institute, ngam teffugo e aynugo sankittol viriis.
Russia deployed facial recognition technology to detect quarantine breakers.
Russiya wangini dabare maandirɗum yeeso ngam maandugu yimɓe je yiɗa wondugo ha seera.
Italian regional health commissioner Giulio Gallera said he has been informed by mobile phone operators that "40% of people are continuing to move around anyway".
Arduɗo do jam ɓaandu lesdi Italy Giulio Gallera wi'i arduɓe telefon matini mo'o yo'o "40% yimɓe ɗon tokkita tarugo".
German government conducted a 48 hours weekend hackathon with more than 42.000 participants.
Ngomna Jaamani sallini ekkitol gal yurnol matinolji ha nder njamɗe be yimɓe 42000.
Also the president of Estonia, Kersti Kaljulaid, made a global call for creative solutions against the spread of coronavirus.
Fahin, Jagorɗo Estoniya, Kersti Kaljulaid, ewni yimɓe jur ngam dabareji ummatore nder aandalji kanduɗum do sankittol koronaviriis.
Individuals may experience distress from quarantine, travel restrictions, side effects of treatment or fear of the infection itself.
Yimɓe footi heɓɓa larula ngam wondugo ha seera, haɗɗol jaahangalji, sababuji hurgol be hulol nyau man.
BBC quoted Rory O'Connor in saying, "Increased social isolation, loneliness, health anxiety, stress and an economic downturn are a perfect storm to harm people's mental health and wellbeing."
BBC lorniti ko Rory O'Connor be wi'ugo, "Wondugo ha seera ummatore je ɓuri, wondugo feerejo, nummol do jam ɓaandu, tampere be ustol mardi lati bana dulluru ngam gaanyugo jam hakkilo e jam woore yimɓe".
The disease may take a mild course with few or no symptoms, resembling other common upper respiratory diseases such as the common cold.
Nyau ndu footi yocca yahde deydey be mandolji seeɗa mala woda, je ɗon naandi irin nyauji lawol pofɗe je do bana ndamba meere.
Mild cases typically recover within two weeks, while those with severe or critical diseases may take three to six weeks to recover.
Nyauɓe je ɗon mari nyau deydey tan ɓurna fu nyamɓittan ha nder asawere ɗiɗi, ɓe'en je mari nyau je nyaɗi mala je ɓuri nyauɗugo footi hoosa asaweji tati ha joowey e go'o ha nyamɓitta.
Pregnant women may be at higher risk for severe infection with COVID-19 based on data from other similar viruses, like SARS and MERS, but data for COVID-19 is lacking.In some people, COVID-19 may affect the lungs causing pneumonia.
Rewɓe be reedu footi mara sababuji ɓuri nyaɗugo ngam COVID-19 do mandolji je tawama do irin koronaviriis ndu, bana SARS be MERS, amma matinolji do COVID-19 woda. Ha yimɓe feere, COVID-19 footi memma fuffu e hokka pneumonia.
In those most severely affected, COVID-19 may rapidly progress to acute respiratory distress syndrome (ARDS) causing respiratory failure, septic shock or multi-organ failure.
Ha ɓe'en je nyau ɗon torra masin, COVID-19 footi yotta ha nyau pofɗe je deydey (ARDS) ko ɗon wada saɗirma nder pofɗe, duwinol mala nyau kujeji feere nder ɓaandu.
Complications associated with COVID-19 include sepsis, abnormal clotting and damage to the heart, kidneys and liver.
Saɗirmaji be COVID-19 larni nawnol ɓaandu, ɗajjugo mala nawnugo bernde, ɓooye be hengre.
Clotting abnormalities, specifically an increase in prothrombin time, have been described in 6% of those admitted to hospital with COVID-19, while abnormal kidney function is seen in 4% of this group.
Ɗajjol iyam je wonay be lawol, be ɓesdare wakati prothrombin, sappinotto ha 6% ɓe'en je neldama ha suudu lekki be COVID-19, be 4% ɓooye je huwata boɗɗum ha nder geeɓe.
Approximately 20-30% of people who present with COVID-19 demonstrate elevated liver enzymes (transaminases).
Ɓadi 20-30% yimɓe je mari COVID-19 ɗon sappina neebam hengre (transaminaseji) mauni.
According to the same report, the median time between onset of symptoms and death was ten days, with five being spent hospitalised.
Ha limte batakkewol ndu, wakati cakkare digga fuɗɗam mandolji ha wade woni no balɗe sappo, be joowey wondi ha suudu lekki.
However, patients transferred to an ICU had a median time of seven days between hospitalisation and death.
Ama, nyauɓe je ɓe neldi ha nder ICU ɗon mari wakati balɓe joowey e ɗiɗi ha kunde wondugo ha suudu lekki be mayde.
In a study of early cases, the median time from exhibiting initial symptoms to death was 14 days, with a full range of six to 41 days.
Ha nder ekkitol arandere nyauɓe, wakati cakkare diga fuɗɗam mandolji ha mayde lati no balɗe 14, be balɗe yahan diga joowey e go'o ha 41.
In a study by the National Health Commission (NHC) of China, men had a death rate of 2.8% while women had a death rate of 1.7%.
Ha nder ekkitol National Health Commission (NHC) Cayna, worɓe mari no limtol mayde 2.8% e rewɓe mari no limtol wade 1.7%.
Histopathological examinations of post-mortem lung samples show diffuse alveolar damage with cellular fibromyxoid exudates in both lungs.
Lartolji tariya nyau ndu ha nder leeku fuffu mayɗo ɗon sappina diffuse alveolar damage be cellular fibromyxoid exudateji ha nder fuffu ɗiɗi fu.
Viral cytopathic changes were observed in the pneumocytes.
Saanjolji viriis ha nder cellji tawama ha nder pneumocyteji.
The lung picture resembled acute respiratory distress syndrome (ARDS).
Foto fuffu naandi no nyau saɗirma pofɗe (ARDS).
In 11.8% of the deaths reported by the National Health Commission of China, heart damage was noted by elevated levels of troponin or cardiac arrest.
Ha kunde 11.8% mayɓe je ɗon matini gal National Health Commission Cayna, memmol ɓernde matinotto be limtol tropinin mala darnol ɓernde.
According to March data from the United States, 89% of those hospitalised had preexisting conditions.Availability of medical resources and the socioeconomics of a region may also affect mortality.
Ha sappinol matinolji Maars ha Lesɗe America, 89% je ɓe'en je wondi ha suudu lekki e mari saɗirmaji feere. Wondugo dabareji jam ɓaandu jonde ummatore be mardi wakkere ndu footi memma limtol mayde
Estimates of the mortality from the condition vary because of those regional differences, but also because of methodological difficulties.
Limtol mayde ngam saɗirma ɗon saanja ngam feeretirolji wekkereji ndu, amma bo'o ngam larulaji yahde laahal.
The under-counting of mild cases can cause the mortality rate to be overestimated.
Limgal nyauɓe je maray larula jur footi ɓesda limtol mayde.
However, the fact that deaths are the result of cases contracted in the past can mean the current mortality rate is underestimated.
Amma, ko je mayde lati sappinol nyauɓe je nangi nyau ndu ara footi wi'a yo'o limtol mayde jonta ɗon lessi.
Smokers were 1.4 times more likely to have severe symptoms of COVID-19 and approximately 2.4 times more likely to require intensive care or die compared to non-smokers.Concerns have been raised about long-term sequelae of the disease.
Foɗɗooɓe woni no bana ɗon sappina mandolji nyau je nyaɗum ha COVID-19 nde 1.4 be ɓadi nde 2.4 je bana ɓuri marugo haaje suklare feere mala maya to foondi be ɓe'en je wala foɗɗugo. Wodi larulaji je wangi ngam ko nyau man accatta ha ɓawo to hurgi.
The Hong Kong Hospital Authority found a drop of 20% to 30% in lung capacity in some people who recovered from the disease, and lung scans suggested organ damage.
Hong Kong Hospital Authority sappini jippol 20% be 30% ha nder sembe fuffu ha yimɓe je nyamɓitti nder nyau ndu, be lartol fuffu je ɗon no holla sampittol.
This may also lead to post-intensive care syndrome following recovery.
Ndu footi yara ha nyau suklugo do jam ɓandu ha ɓawo nyamɓittol.
As of March 2020, it was unknown if past infection provides effective and long-term immunity in people who recover from the disease.
Ha Maars 2020, yimɓe aanda no to nyau je sallingo ɗon hokka fadol ha yimɓe je yamɓittama.
Immunity is seen as likely, based on the behaviour of other coronaviruses, but cases in which recovery from COVID-19 have been followed by positive tests for coronavirus at a later date have been reported.
Fadol lati bana footi, do gikku koronaviriisji feere, amma nyauɓe je nyamɓitti ha COVID-19 tokkitotto be lartolji je ɗon sappina o ɗon mari nyau woni.
These cases are believed to be worsening of a lingering infection rather than re-infection.
Irin hurgolji ndu tammi bana nyau feere je ɗon ɗaayi do wonugo raɓɓol keese.
The virus is thought to be natural and have an animal origin, through spillover infection.
Viriis ndu ɗon tammi bana woni ha ladde e wangi gal daabaji, gal nyau je hebbi timmi.
The actual origin is unknown, but by December 2019 the spread of infection was almost entirely driven by human-to-human transmission.
En aanda gal toy wanngi, amma gal lewru Desambre 2019 yaajugo nyau man salli ɓurna yimɓe, oya ha oya.
A study of the first 41 cases of confirmed COVID-19, published in January 2020 in The Lancet, revealed the earliest date of onset of symptoms as 1 December 2019.
Jaangirde arandere nyauɓe 41 je ɗon aandi mari COVID-19, je wurti ha Zaanviye 2020 ha Lancet, sappini wakati je mandolji je ɓuri wangugo be laugel ha 1 Desambre 2019.
Official publications from the WHO reported the earliest onset of symptoms as 8 December 2019.
Sappinolji WHO sappini arandere fuɗɗam wangol mandolji ha 8 Desambre 2019.
Several measures are commonly used to quantify mortality.
Dabareji ɗuɗɗum ɗon ɓurna naffa ngam limtol mayɓe.
These numbers vary by region and over time and are influenced by the volume of testing, healthcare system quality, treatment options, time since initial outbreak and population characteristics such as age, sex and overall health.
Limtolji ndu ɗon saanja be wakare e be wakati e memmotto gal lartolji, daraja dabare jam ɓaandu, suɓɓolji hurgol, wakati diga fuɗɗam aranool wangirde nyau be gikku ummatore bana duɓɓi, baadal be jam ɓaandu fu.
In late 2019, WHO assigned the emergency ICD-10 disease codes U07.1 for deaths from lab-confirmed SARS-CoV-2 infection and U07.2 for deaths from clinically or epidemiologically diagnosed COVID-19 without lab-confirmed SARS-CoV-2 infection.The death-to-case ratio reflects the number of deaths divided by the number of diagnosed cases within a given time interval.
Ha ragare 2019, WHO hokki jaawal lamba nyau ICD-10 U07.1 ngam mayde diga fammugo nyau SARS-CoV-2 ha nder suudu lartol be U07.1 ngam mayde je tawake ha suudu lekki mala gal nyau COVID-19 bila SARS-CoV-2 je nastay ha suudu lekki. Limtol nyauɓe ha kunde maybe larni limgal yimɓe je maynama sendugo man be limgal yimɓe je ɗon mari nyau man ha nder wakati je ɗon aandin.
Based on Johns Hopkins University statistics, the global death-to-case ratio is 6.9% (153,822/2,240,191) as of 17 April 2020.
Wondugo do sappinolji Johns Hopkins University, limtol wade do nyauɗo woni 6.9% (153,822/2,240,191) diga 17 Aviiril 2020.
The number varies by region.Other measures include the case fatality rate (CFR), which reflects the percent of diagnosed individuals who die from a disease, and the infection fatality rate (IFR), which reflects the percent of infected individuals (diagnosed and undiagnosed) who die from a disease.
Limgal ɗon saanja be wakkere. Dabareji feere larni limtol mayde (CFR), je ɗon sappina limgal yimɓe je mari no nyau e mayi, be limtol raɓɓol (IFR), je ɗon holla limtol yimɓe (je larti be lartay) je mayi ngam nyau feere.
These statistics are not time bound and follow a specific population from infection through case resolution.
Sappinolji ndu larnay wakati e ɗon tokkita ummatore feerejo ngam nyau gal hurgol nyau.
While not all infected people develop antibodies, the presence of antibodies may provide information about how many people have been infected.
Ko to na kala moy fu footi ummina kujeji fadugo ɓaandu, wondugo maɓɓe footi hokka matinolji do noy yimɓe jur raɓɓi nyau ndu.
In the epicentre of the outbreak in Italy, Castiglione d'Adda, a small village of 4600, 80 (1.7%) are already dead.
Ha nder cakkare nyau ha Italy, Castiglione d'Adda, wuro pamarron be yimɓe 4600, be 80 (1.7%) maynama timmi.
In Gangelt, the disease was spread by Carnival festivals, and spread to younger people, causing a relatively lower mortality, and not all COVID-19 deaths may have been formally classified as such.
Ha Gangelt, nyau sankitti gal juldeji Carnival, e raɓɓi ummatore sukkaɓe, be limtol mayde seeɗa tan, e na kala mayɗo ngam COVID-19 nastan ha nder geeɓe ndu.
Furthermore, the German health system has not been overwhelmed.
Fahin bo'o, dabare jam ɓaandu Jaamani ɓuray tawon.
In the Netherlands, about 3% may have antibodies, as assessed from blood donors.
Ha Netherlands, ɓadi 3% footi mara fadooɓe ɓaandu, bana ko ɗo sappina iyam hokkooɓe.
69 (0.004% of the population) have been confirmed to have died from COVID-19.
69 (0.004% ummatore) aandi bana mayi ngam COVID-19.
The impact of the pandemic and its mortality rate are different for men and women.
Sembe nyau be.limtol mayde ɗon feere-feere ha kunde worɓe be rewɓe
Mortality is higher in men in studies conducted in China and Italy.
Limtol mayde ɓuri maunugo ha worɓe ha nder ekkitolji je salli ha Cayna be Italy.
The highest risk for men is in their 50s, with the gap between men and women closing only at 90.
Sababu je ɓuri maunugo ha worɓe ɗon gal duɓɓi 50, be feeretirol ha kunde worɓe be rewɓe ha duɓɓi 90.
In China, the death rate was 2.8 percent for men and 1.7 percent for women.
Ha Cayna, limtol mayde woni worɓe 2.8 nder temere be worɓe 1.7 ha nder temere.
The exact reasons for this sex-difference is not known, but genetic and behavioural factors could be a reason.
Ujaji gonga ngam feeretirol worɓe be rewɓe aandakke, amma geneji be gikku footi wona uja ndu.
Sex-based immunological differences, lesser prevalence of smoking in women and men developing co-morbid conditions such as hypertension at a younger age than women could have contributed to the higher mortality in men.
Feeretirolji fadol ɓaandu ha kunde worɓe be rewɓe, lessugo be foɗɗol ha rewɓe be worɓe je ɗon sappina sababuji nyau bana nyau illol iyam be semɓe diga sukkajo do rewɓe footi ɓesdi no limtol mayde jur ha worɓe.
In Europe, 57% of the infected individuals were men and 72% of those died with COVID-19 were men.
Ha Erop, 57% yimɓe je mari nyau woni worɓe be 72% nyauɓe je mayi ngam COVID-19 woni worɓe.
As of April 2020, the US government is not tracking sex-related data of COVID-19 infections.
Ha Aviiril 2020, ngomna Lesɗe America larata matinolji je larni baadal nyauji COVID-19.
Research has shown that viral illnesses like Ebola, HIV, influenza and SARS affect men and women differently.
Teffol sappini yo'o nyauji viriis bana Ebola, HIV, ndamba be SARS ɗon memma worɓe be rewɓe be feerejo.
A higher percentage of health workers, particularly nurses, are women, and they have a higher chance of being exposed to the virus.
Ɗuɗɗum cakka huwooɓe do jam ɓaandu, lekkitaɓe, rewbe, e ɓe ɗon mari sa'a maungel ngam wondugo ha yeeso viriis.
The World Health Organization announced on 11 February 2020 that the official name of the disease would be "COVID-19".
Geeɓe Duniyaru do Jam Ɓaandu matini ha 11 Feviriye 2020 yo'o inde nyau ndu wonan "COVID-19".
WHO chief Tedros Adhanom Ghebreyesus explained that CO stands for corona, VI for virus, D for disease, and 19 for when the outbreak was first identified: 31 December 2019.
Arduɗo WHO Tedros Adhanom Ghebreyesus holli yo'o CO yiɗi wi'ugo Korona, VI bo'o viriis, D ngam nyau, be 19 ngam wakati aranool wangol nyau ndu: 31 Desambre 2019.
The name had been chosen to avoid references to a specific geographical location (e.g. China), animal species or group of people, in line with international recommendations for naming aimed at preventing stigmatisation.The virus that causes COVID-19 is named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Inde ndu suɓɓotto ngam tato hawta be inde wakkere feerejo (bana Cayna), asngol daaba mala gee
The WHO additionally uses "the COVID-19 virus" and "the virus responsible for COVID-19" in public communications.
WHO ɗon ɓesda bo'o "viriis COVID-19" be "viriis je ɗon hokka COVID-19" ha nder ngewte ummatore maɗa.
Both the disease and virus are commonly referred to as "coronavirus".
Nyau be viriis ɗiɗi fu ɗon ewni bana "koronaviriis".
During the initial outbreak in Wuhan, China, the virus and disease were commonly referred to as "coronavirus" and "Wuhan coronavirus".
Ha fuɗɗam wangol nyau ha Wuha, Cayna, viriis be nyau ewnotto no bana "koronaviriis" be "koronaviriis Wuhan".
In January 2020, WHO recommended 2019-nCov and 2019-nCoV acute respiratory disease as interim names for the virus and disease in accordance with 2015 guidance against using locations in disease and virus names.
Ha Zaanviye 2020, WHO feeli nyau pofɗe je deydey 2019-nCov be 2019-nCoV bana inde je hiddeko viriis be nyau bana feeloji fadol 2015 ngam watugo inde wakkere nyau be viriis.
The official names COVID-19 and SARS-CoV-2 were issued on 11 February 2020.
Inde gonga COVID-19 be SARS-CoV-2 wurti ha 11 Feviriye 2020.
Due to capacity limitations in the standard supply chains, some digital manufacturers are printing healthcare material such as nasal swabs and ventilator parts.
Ngam dabareji je ɗon mari keerolji ha nder soddugo kujeji, taggooɓe kujeji ɗon wurtina kujeji je larni jam ɓaandu bana kujeji hoosugo leeku be ordoji pofɗe.
In one example, when an Italian hospital urgently required a ventilator valve, and the supplier was unable to deliver in the timescale required, a local startup reverse-engineered and printed the required 100 valves overnight.
Ha nder sappinol gooto, ha wakati je suudu lekki feere ha Italy emmi kuje ordo fartugo hendu nder jaawal, sippoowo footay wangina ɗum ha nder wakati je ɗon emmi, sippoowo feere ha wakkere je wala inde larti kuje man e wurtini 100 be jemma.
After the initial outbreak of COVID-19, conspiracy theories, misinformation and disinformation emerged regarding the origin, scale, prevention, treatment and other aspects of the disease and rapidly spread online.
Ha ɓawo arandere nyau COVID-19, ngewte tufle, matinolji je yahay mala lasbinugo matinollji ɗon no dogga do internati ngam ko larni wangirde, yahde, aynol, hurgol be mandolji nyau.
Humans appear to be capable of spreading the virus to some other animals.
Yimɓe lati bana footi sankitta viriis ha nder daabaji feere.
The study failed to find evidence of viral replication in pigs, ducks, and chickens.
Ekkitol ndu heɓɓay sappinolji nuftol viriisji ha nder gaduji, kanarji, be goortoɗe.
No medications or vaccine is approved to treat the disease.
Wala lekki mala baatal je jarfi footi hurga nyau.
International research on vaccines and medicines in COVID-19 are underway by government organisations, academic groups and industry researchers.
Teffol ha nder duniyaru do baatalji be lekki ha COVID-19 ɗon haɓda ngam wurtinugo ndu gal geeɓeji, geeɓe jam'iareji be teffooɓe tagooɓe.
In March, the World Health Organization initiated the "SOLIDARITY Trial" to assess treatment effects of four existing antiviral compounds with the most promise of efficacy.
Ha Maars, Geeɓe Duniyaru do Jam Ɓaandu fuɗɗi be "SOLIDARITY Trial" ngam lartugo sababuji hurgol hawtirde lekki nay je ɗon sappina naffitirki ɗuɗɗum.
There is no available vaccine, but various agencies are actively developing vaccine candidates.
Wala baatal je ɗon wondi, amma geeɓeji jur ɗon huwa do baatalji foondol be sembe
Previous work on SARS-CoV is being utilised because SARS-CoV and SARS-CoV-2 both use the ACE2 receptor to enter human cells.
Kuɗe sallingo do SARS-Cov naffi ngam SARS-CoV BE sars cOv-2 ɗiɗi fu ɗon huwa be ACE2 ngam nastugo nder ɓali neɗɗo.
There are three vaccination strategies being investigated.
Wodi dabareji baatal da lartol jonta.
First, researchers aim to build a whole virus vaccine.
Aranool, teffooɓe yiɗi wanginugo baatal viriis man sam.
The use of such a virus, be it inactive or dead, aims to elicit a prompt immune response of the human body to a new infection with COVID-19.
Huwidugo be irin viriis ndu, ko to huwata mala maynama, yiɗi findinugo jabbuye ngam haɓre ha nder ɓaandu neɗɗo ha nyau COVID-19 keese.
A second strategy, subunit vaccines, aims to create a vaccine that sensitises the immune system to certain subunits of the virus.
Dabare ɗiɗaɓool, geeɓe baatalji, yiɗi wurtinugo baatal je ɗon findina fadol ɓaandu ngam geeɓeji viriis feere.
In the case of SARS-CoV-2, such research focuses on the S-spike protein that helps the virus intrude the ACE2 enzyme receptor.
Bana ko larni SARS-CoV-2, irin teffol don larni protein S-spike je don mballita virris nasta nder neebam je jabbitata ACE2.
A third strategy is that of the nucleic acid vaccines (DNA or RNA vaccines, a novel technique for creating a vaccination).
Dabare tataɓool lati je baatalji nucleic acid (DNA mala RNA, dabare keese ngam wanginugo baatal).
Experimental vaccines from any of these strategies would have to be tested for safety and efficacy.On 16 March 2020, the first clinical trial of a vaccine started with four volunteers in Seattle.
Bataalji foondol ha cakka gooto dabareji ndu sey larta ngam jam be naffitirki. Ha 16 Maars 2020, aranool lartol baatal fuɗɗi be foondooɓe nay ha nay.
The vaccine contains a harmless genetic code copied from the virus that causes the disease.Antibody dependent enhancement has been suggested as a potential challenge for vaccine development for SARS-COV-2, but this is controversial.
Baatal ɗon mari lamɓa gene je wala sababu je hoosi ha viriis je ɗon hokka viriis. Fadoowo ɓaandu feelama bana baatal je footi hurga SARS-CoV-2, amma teffooɓe feere yarday ndu.
There are more than 300 active clinical trials underway as of April 2020.
Wodi ɓuri foondolji suudu lekki 300 do teffol diga Aviiril 2020.
Seven trials were evaluating already approved treatments for malaria, including four studies on hydroxychloroquine or chloroquine.
Foondolji joowey e ɗiɗi ɗon larta lekki je ɗon yardi nder hurgolji paaɓooje, be ekkitolji nay do hydroxychloroquine mala chloroquine.
Repurposed antiviral drugs make up most of the Chinese research, with nine phase III trials on remdesivir across several countries due to report by the end of April.
Lekki mbardugo viriisji je ɗon larti woni laahal ɓurna teffolji ha Cayna, be foondolji Yaɓɓorde III do remdesivir ha nder lesɗe jur ngam lartol ragare Aviiril.
A dynamic review of clinical development for COVID-19 vaccine and drug candidates was in place, as of April 2020.Several existing antiviral medications are being evaluated for treatment of COVID-19, including remdesivir, chloroquine and hydroxychloroquine, lopinavir/ritonavir and lopinavir/ritonavir combined with interferon beta.
Lartol huwidugo do baatal be lekki COVID-19 je warangu fuɗɗi wangugo, diga lewru Aviiril 2020.
There is tentative evidence for efficacy by remdesivir, as of March 2020.
Wodi tammunde sappinol ngam naffitirki gal remdesivir, ha Maars 2020.
Clinical improvement was observed in patients treated with compassionate-use remdesivir.
Yahde ha nder foondol ha suudu lekki tawama ha nyauɓe je ɗon hoosa remdesivir be hakkika.
Phase III clinical trials are being conducted in the US, China and Italy.Chloroquine, previously used to treat malaria, was studied in China in February 2020, with preliminary results.
Foondolji Yaɓɓorde III ha suudu lekki je salli ha Lesɗe America, Cayna be Italy. Chloroquine, ha aran ɗon no naffa ngam hurgol malaria, lartotto ha Cayna ha Feviriye 2020, be sappinolji aranool.
However, there are calls for peer review of the research.
Amma, wodi ewnanduji ngam lartol teffol ndu.
Korean and Chinese Health Authorities recommend the use of chloroquine.
Arduɓe Jam ɓaandu Korea be Cayna ɗon feela hoosugo chloroquine.
However, the Wuhan Institute of Virology, while recommending a daily dose of one gram, notes that twice that dose is highly dangerous and could be lethal.
Amma, Wuhan Institute of Virology, feelugo hoosugo lekki dose gram woore ha nder balɗe, ɗon matina yo'o dose ndu mari sababu ɗuɗɗum e footi mbara.
On 28 March 2020, the FDA issued an emergency use authorisation for hydroxychloroquine and chloroquine at the discretion of physicians treating people with COVID-19.The Chinese 7th edition guidelines also include interferon, ribavirin or umifenovir for use against COVID-19.
Ha 28 Maars 2020, FDA wurtini jarfuye ngam jaawal do hydroxychloroquine be chloroquine bila aandinugo ha lekkitoɓe je ɗon sukla do hurgol yimɓe je ɗon mari COVID-19. Batakkewol sappinol 7 ɗon larni interferon, ribavirin mala umifenovir ngam hurgugo COVID-19.
Preliminary data indicate that high doses of ribavirin are necessary to inhibit SARS-CoV-2 in vitro.
Arandere matinolji holli yo'o doseji ribavirin ɗon wodi naffitirki do tuttol SARS-CoV-2 in vitro.
Nitazoxanide has been recommended for further in vivo study after demonstrating low concentration inhibition of SARS-CoV-2.Studies have demonstrated that initial spike protein priming by transmembrane protease serine 2 (TMPRSS2) is essential for entry of SARS-CoV-2 via interaction with the ACE2 receptor.
Nitazoxanide feelama ngam ekkitolji in vivo ha ɓawo sappinol concentration tuttol SARS-CoV-2 ɗon lessi. Ekkitolji sappini yo'o ta'ugo arandere protein spike gal transmembrane protease serine 2 (TMPRSS2) lati kanduɗum ngam SARS-CoV-2 gal kugal be jaɓɓowo ACE2.
The studies of chloroquine and hydroxychloroquine with or without azithromycin have major limitations that have prevented the medical community from embracing these therapies without further study.Oseltamivir does not inhibit SARS-CoV-2 in vitro and has no known role in COVID-19 treatment.
Ekkitolji do chloroquine be hydroxychloroquine be mala bila azithromycin ɗon wodi keleewolji je haɗɗi ummatore lekki amin ngam jaɓɓugo ndu bila ekkitolji feere. Oseltamivir tuttata SARS-CoV-2 in vitro e kugal ngel aandakke ha nder hurgol COVID-19.
Cytokine storm can be a complication in the later stages of severe COVID-19.
Dullure cytokine footi wona sababu ha nder yahdeji COVID-19 feere je nyaɗum.
There is evidence that hydroxychloroquine may have anti-cytokine storm properties.Tocilizumab has been included in treatment guidelines by China's National Health Commission after a small study was completed.
Wodi sappinol yo'o hydroxychloroquine footi mara dabareji willugo dullure cytokine. Tocilizumab nastinama ha nder dabareji hurgol gal China's National Health Commission ha ɓawo timminol ekkitol feere pamarron.
It is undergoing a phase 2 non randomised test at the national level in Italy after showing positive results in people with severe disease.
Don sallina ta'irde 2 je lartol bila subol ha nder lesdi Italy ha bawo sappinol be tawi nyau ha yimbe be nyau je don nyadi.
Combined with a serum ferritin blood test to identify cytokine storms, it is meant to counter such developments, which are thought to be the cause of death in some affected people.
Hawti be lartol neebam ferriitin iyam ngam maandugo dulluru cytokine, kugal man lati haɗɗugo irin yahdeji ndu, je lati bana ɗaaɗol mayde ha yimɓe feere je ɗon mari nyau ndu.
The interleukin-6 receptor antagonist was approved by the FDA based on retrospective case studies for treatment of steroid refractory cytokine release syndrome induced by a different cause, CAR T cell therapy, in 2017.
Jaɓɓowo interleukin-6 antagonist ɗonj jarfi gal FDA do ekkitolji je sallingo ngam hurgol steroid refractory cytokine je wangi gal hurgol cell CAR T, he 2017.
To date, there is no randomised, controlled evidence that tocilizumab is an efficacious treatment for CRS.
Haande, walla sappinol bana ni, je aandintiri be fakatre yo'o tocilizumab lati kanduɗum ngam hurgol CRS.
Transferring purified and concentrated antibodies produced by the immune systems of those who have recovered from COVID-19 to people who need them is being investigated as a non-vaccine method of passive immunisation.
Sallinugo fadooɓe ɓaandu je ɗon laɓɓi e hawti je ɓaandu yimɓe je hurgotto ngam COVID-19 wangini ha yimɓe je mari haaje man ɗon do lartol bana dabare fadol bila aandugo.
This strategy was tried for SARS with inconclusive results.
Dabare ndu fondotto ngam SARS amma hokkay ɓibe.
Viral neutralisation is the anticipated mechanism of action by which passive antibody therapy can mediate defence against SARS-CoV-2.
Mbardugo viriis lati bana dabare kugal gal ndu hurgol gal fadoowo ɓaandu je aandakke footi wangina fadol ngam SARS-CoV-2.
Other mechanisms however, such as antibody-dependent cellular cytotoxicity and/or phagocytosis, may be possible.
Kujeji feere, bana ko mbiyotto cellular cytotoxity e/mala nyamtidugo, footi wona.
Other forms of passive antibody therapy, for example, using manufactured monoclonal antibodies, are in development.
Irin dabareji hurgol gal fadoowo ɓaandu je aandakke, bana sappinol, gal fadooɓe ɓaandu je mari kosngal gooto, ɗon yahde.
Production of convalescent serum, which consists of the liquid portion of the blood from recovered patients and contains antibodies specific to this virus, could be increased for quicker deployment.
Wurtinol neebam iyam ha goɗɗo je ɗon do hurgol, je lati ndiyam iyam he hoccama ha nyauɓe je nyamɓitti e ɗon mari faɗooɓe ɓaandu do viriis, footi ɓesdotto ngam jabbugo be laugel.
Coronavirus diseases, a group of closely related syndromes
Nyau koronaviriis, geeɓe mandolji je ɗon hawti
Li Wenliang, a doctor at Central Hospital of Wuhan, who later contracted and died of COVID-19 after raising awareness of the spread of the virus.
Li Wenliang, lekkitajo ha Central Hospital Wuhan, je nangi nyau COVID-19 e je mayi ha ɓawo je o ewni hakkilo yimɓe do sankittol viris.